Magnus Medical Announces Uninterrupted 2026 Payment Stability for SAINT Neuromodulation in CMS OPPS Final Rule

BURLINGAME, Calif.--(BUSINESS WIRE)--Magnus Medical, Inc., the company behind SAINT®, the first and only FDA-cleared, rapid-remission therapy for Major Depressive Disorder (MDD), today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized the 2026 Hospital Outpatient Prospective Payment System (OPPS) rule, preserving the existing payment structure for its breakthrough SAINT neuromodulation therapy. This decision ensures that Medicare patients with MDD will continue to have access to SAINT therapy in hospital outpatient settings.

“Hospitals and clinicians have embraced SAINT because they are seeing that rapid remission from chronic debilitating depression is now possible,” said Brandon Bentzley, M.D., Ph.D., co-founder and CSO of Magnus Medical.

Share

“For people living with depression, many of whom have struggled for years, access to rapid, effective treatment can change the course of life,” said Christian Gormsen, CEO of Magnus Medical. “By preserving the payment structure for SAINT, CMS has reaffirmed its commitment to ensuring patients have access to this life-changing, personalized accelerated treatment. This decision allows hospitals to continue offering real hope and lasting remission to people who have exhausted all other options.”

“Magnus will continue expanding access to SAINT across the country with stable reimbursement secured, working alongside leading hospital partners and providers to reach even more people living with MDD and treatment-resistant depression,” continued Gormsen.

In its Final Rule, CMS confirmed that SAINT’s four Category III CPT codes (0889T-0892T) will retain their current Ambulatory Payment Classification (APC) assignments for 2026. Notably, CMS attributed part of this decision to the compelling supportive comments submitted by healthcare providers, hospital systems and patient advocates during the rulemaking comment period.

“Hospitals and clinicians have embraced SAINT because they are seeing that rapid remission from chronic debilitating depression is now possible,” said Brandon Bentzley, M.D., Ph.D., co-founder and CSO of Magnus Medical. “We are deeply grateful to the providers, hospital partners and patient advocates who commented during this process, as well as to CMS for their powerful commitment to making life-saving brain health therapies more accessible. This decision gives the healthcare community the stability to keep expanding access to treatments that achieve rapid remission for depression in a dependable and sustainable way.”

About Magnus Medical and SAINT Neuromodulation

Magnus Medical, Inc. is a privately held brain health technology company delivering accelerated, noninvasive, precision neuromodulation therapy and rapid remission for serious neuropsychiatric conditions. Its first product, SAINT®, is the first and only FDA-cleared rapid-remission therapy for MDD and TRD, with pivotal clinical trials showing that 79% of patients achieved remission in an average of just 2.6 days. Designated an FDA Breakthrough Device and the first mental health therapy to receive CMS innovation funding through the New Technology Add-on Payment (NTAP) and New Technology APC programs, SAINT is now available through a growing network of providers nationwide. Clinical trials are ongoing for additional neuropsychiatric conditions, including obsessive-compulsive disorder, bipolar depression and postpartum depression (not yet FDA-cleared). Learn more at www.magnusmed.com.